Cantor Fitzgerald L. P. Cuts Stock Position in OnKure Therapeutics, Inc. $OKUR

Cantor Fitzgerald L. P. decreased its holdings in shares of OnKure Therapeutics, Inc. (NASDAQ:OKUR) by 26.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 491,863 shares of the company’s stock after selling 177,676 shares during the quarter. Cantor Fitzgerald L. P. owned about 3.63% of OnKure Therapeutics worth $1,353,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new stake in OnKure Therapeutics in the 2nd quarter valued at $25,000. Bailard Inc. acquired a new position in shares of OnKure Therapeutics during the second quarter worth about $34,000. Rangeley Capital LLC purchased a new stake in shares of OnKure Therapeutics in the second quarter worth about $71,000. GSA Capital Partners LLP boosted its position in shares of OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock worth $163,000 after buying an additional 37,459 shares during the period. Finally, Prosight Management LP grew its stake in shares of OnKure Therapeutics by 67.8% in the third quarter. Prosight Management LP now owns 267,959 shares of the company’s stock valued at $737,000 after buying an additional 108,267 shares in the last quarter. 90.98% of the stock is owned by hedge funds and other institutional investors.

OnKure Therapeutics Price Performance

NASDAQ:OKUR opened at $3.78 on Friday. The firm has a 50-day moving average of $2.84 and a two-hundred day moving average of $2.87. The stock has a market cap of $51.21 million, a P/E ratio of -0.86 and a beta of 0.45. OnKure Therapeutics, Inc. has a 1-year low of $1.70 and a 1-year high of $5.28.

OnKure Therapeutics (NASDAQ:OKUR) last announced its earnings results on Monday, March 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.16. As a group, equities analysts expect that OnKure Therapeutics, Inc. will post -4.05 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on OKUR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. Wall Street Zen upgraded OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, OnKure Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $34.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.